Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study
- PMID: 16519785
- DOI: 10.1111/j.1085-9489.2006.00066.x
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study
Abstract
Antiretroviral toxic neuropathy causes morbidity in human immunodeficiency virus (HIV) patients under dideoxynucleoside therapy, benefits only partially from medical therapy, and often leads to drug discontinuation. Proposed pathogeneses include a disorder of mitochondrial oxidative metabolism, eventually related to a reduction of mitochondrial DNA content, and interference with nerve growth factor activity. Carnitine is a substrate of energy production reactions in mitochondria and is involved in many anabolic reactions. Acetyl carnitine treatment promotes peripheral nerve regeneration and has neuroprotective properties and a direct analgesic role related to glutamatergic and cholinergic modulation. The aim of this study was to evaluate acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in HIV patients. Twenty subjects affected by painful antiretroviral toxic neuropathy were treated with oral acetyl-l-carnitine at a dose of 2,000 mg/day for a 4-week period. Efficacy was evaluated by means of the modified Short Form McGill Pain Questionnaire with each item rated on an 11-point intensity scale at weekly intervals and by electromyography at baseline and final visit. Mean pain intensity score was significantly reduced during the study, changing from 7.35 +/- 1.98 (mean +/- SD) at baseline to 5.80 +/- 2.63 at week 4 (p = 0.0001). Electrophysiological parameters did not significantly change between baseline and week 4. In this study, acetyl-l-carnitine was effective and well tolerated in symptomatic treatment of painful neuropathy associated with antiretroviral toxicity. On the contrary, no effect was noted on neurophysiological parameters.
Similar articles
-
A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection.HIV Med. 2007 May;8(4):241-50. doi: 10.1111/j.1468-1293.2007.00467.x. HIV Med. 2007. PMID: 17461852 Clinical Trial.
-
Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients.J Peripher Nerv Syst. 1997;2(3):250-2. J Peripher Nerv Syst. 1997. PMID: 10975731 Clinical Trial.
-
An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.J Pain Symptom Manage. 2008 Mar;35(3):299-306. doi: 10.1016/j.jpainsymman.2007.04.015. Epub 2007 Oct 23. J Pain Symptom Manage. 2008. PMID: 17959343 Clinical Trial.
-
Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.CNS Drugs. 2007;21 Suppl 1:25-30; discussion 45-6. doi: 10.2165/00023210-200721001-00004. CNS Drugs. 2007. PMID: 17696590 Review.
-
Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy.Ann Pharmacother. 2008 Nov;42(11):1686-91. doi: 10.1345/aph.1L201. Epub 2008 Oct 21. Ann Pharmacother. 2008. PMID: 18940920 Review.
Cited by
-
Transplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine.PLoS One. 2013;8(2):e55753. doi: 10.1371/journal.pone.0055753. Epub 2013 Feb 7. PLoS One. 2013. PMID: 23409035 Free PMC article.
-
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.PLoS One. 2010 Dec 28;5(12):e14433. doi: 10.1371/journal.pone.0014433. PLoS One. 2010. PMID: 21203440 Free PMC article.
-
Treatment with acetyl-L-carnitine exerts a neuroprotective effect in the sciatic nerve following loose ligation: a functional and microanatomical study.Neural Regen Res. 2018 Apr;13(4):692-698. doi: 10.4103/1673-5374.230297. Neural Regen Res. 2018. PMID: 29722322 Free PMC article.
-
Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials.Int J Mol Sci. 2014 Nov 5;15(11):20169-208. doi: 10.3390/ijms151120169. Int J Mol Sci. 2014. PMID: 25380523 Free PMC article. Review.
-
Second assessment of NeuroAIDS in Africa.J Neurovirol. 2008 Apr;14(2):87-101. doi: 10.1080/13550280701829793. J Neurovirol. 2008. PMID: 18370346 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical